Nurix Therapeutics Inc recorded a cumulative net loss of $-341 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 211 other companies achieving higher income per employee. While Nurix Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 3535 to 3662.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NRIX Net Income per Employee	(May 31 2026) II. Quarter	(Feb 28 2026) I. Quarter	(Nov 30 2025) IV. Quarter	(Aug 31 2025) III. Quarter	(May 31 2025) II. Quarter
Y / Y Net Income Change	-	-	-	-	-
Net Income per Employee (TTM) $	-1,076,817	-931,483	-834,249	-772,192	-654,006
NRIX's Total Ranking	# 3662	# 3535	# 398	# 240	# 66
Seq. Net Income Change	-	-	-	-	-

NRIX Company Profile >> Back to NRIX Efficiency Comparisons >> Compare NRIX Net Income per Employee to its Competitors

NRIX Net Income per Employee Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 212
Healthcare Sector	# 575
Overall Market	# 3662

Net Income per Employee Statistics
High	Average	Low
$ -58,413	$ -539,074	$ -1,076,817
(Aug 31 2020)		(May 31 2026)

News about Nurix Therapeutics Inc Income per employee

Nurix Therapeutics Raises $175 Million in Upsized Public Offering Amidst Heightened Biotech Market Activity

Nurix Therapeutics, a leading biotech company based in San Francisco, recently announced the pricing of its upsized underwritten public offering of common stock. The company’s successful offering, which totaled $175 million in gross proceeds, reflects the strong investor interest in the biotech sector and Nurix’s promising pipeline of novel therapies.
The offering, which included 10,166,667 shares of common stock priced at $15.00 per share, attracted a diverse group of investors eager to support Nurix’s innovative research and development efforts. In addition to common stock, Nurix also offered certain investors pre-funded warrants to purchase up to 1,500,100 shares of common stock at a purchase price of $14.999 per warrant.

Nurix Therapeutics Announces Proposed Public Offering Amidst Financial Challenges

Nurix Therapeutics Announces Proposed Public Offering Amidst Challenging Financial Performance
SAN FRANCISCO, April 11, 2024 - Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein modulation drugs for cancer and inflammatory diseases, disclosed today its initiation of an underwritten public offering worth $125 million. The offering comprises both common stock and pre-funded warrants for shares of common stock, which will be offered and sold exclusively by Nurix. The company also plans to grant the underwriters a 30-day option to acquire additional shares at the public offering price, subject to market and other conditions. However, the completion, size, and terms of the offering remain uncertain.
This announcement comes in the wake of Nurix Therapeutics recent financial performance. The company recorded a noteworthy cumulative net loss of $-144 million in the 12 months leading up to the fourth quarter of 2023. Unfortunately, this marks a deterioration in its overall ranking compared to the previous quarter, dropping from 517 to 922. While Nurix faces these challenges, the Major Pharmaceutical Preparations industry has witnessed multiple other companies achieving higher income per employee.

Companies with similar Income per Employee for 12 month ending May 31 2026, within Healthcare Sector

Income per Employee

Income 12 month ending May 31 2026

Number of Employees May 31 2026

Date modified: 2026-07-10T05:52:55+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.